Ghana AIDS Commission Announces HIV Preventive Vaccine Rollout by 2026, with Local Production Targeted for 2027
The Ghana AIDS Commission (GAC) has revealed ambitious plans to introduce an HIV preventive vaccine in 2026, marking a pivotal advancement in the nation’s efforts to combat new infections amid rising cases.
Director-General Dr. Prosper Akanbong shared the update during a press briefing in Accra on September 30, 2025, emphasizing the vaccine’s integration into the national HIV prevention strategy.
“As a country, we have already put the vaccine as a main component of our HIV prevention programme,” Dr. Akanbong stated. Initially, supplies will be sourced internationally, but with partnerships involving pharmaceutical firms and support from the German development agency GIZ, local production is slated for late 2026 or early 2027.
“Together with GIZ, we are on track, and in the latter part of 2026 or the early part of 2027, we should be able to produce vaccines for Ghana,” he added.
This initiative aligns with Ghana’s broader push for pharmaceutical self-reliance, building on successes like the 2023 approval of the R21/Matrix-M malaria vaccine—the first country to do so. It also supports the national roadmap for local vaccine manufacturing by 2031, potentially easing reliance on imports and addressing supply chain vulnerabilities.
HIV/AIDS Landscape in Ghana
Ghana faces a persistent HIV challenge, with 2023 data from the GAC and UNAIDS estimating 354,000 people living with HIV—disproportionately affecting women and youth. New infections exceeded 15,000 that year, concentrated in the Ashanti, Greater Accra, and Eastern regions. While antiretroviral therapy access has improved, barriers like stigma, low testing rates, and high transmission among key populations hinder progress. Experts hail the vaccine as a potential “game-changer” for high-risk groups, complementing existing tools like PrEP and condoms.
The GAC plans to detail pilot programs and rollout targets soon, focusing on equitable distribution. This comes alongside other health priorities, such as the upcoming HPV vaccine drive to curb cervical cancer. With GIZ’s technical aid, the effort could position Ghana as a regional leader in HIV innovation, reducing long-term costs and boosting local biotech capacity.
